Understanding what makes children susceptible to acute myeloid leukemia
Official title: Determinants of susceptibility to pediatric acute myeloid leukemia
Funded at Van Andel Research Institute · NIH-11228686 · Data updated 2026-11-12
This study is looking into why some children are more likely to get acute myeloid leukemia (AML) by exploring things like genetics and the environment, and it’s for families affected by this type of cancer to help find better ways to prevent and treat it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Van Andel Research Institute NIH-funded |
| Lab location | 1 site (Grand Rapids, United States) |
| Project start | November 7, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $3,000 |
| NIH project number | 3F99CA294248-01S1 |
| Project ID | NIH-11228686 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children diagnosed with acute myeloid leukemia and their families.
✕Less likely to help
Patients who do not have acute myeloid leukemia or are not at risk for developing it may not benefit from this research.
What this research studies
This research investigates the factors that contribute to the risk of developing pediatric acute myeloid leukemia (AML). By analyzing genetic, environmental, and biological determinants, the study aims to identify why some children are more susceptible to this type of cancer. The approach includes collecting data from affected children and their families to better understand the underlying causes. This information could lead to improved prevention strategies and targeted therapies for those at risk.
Why it matters
Potential benefit: If successful, this research could lead to better prevention and treatment options for children at risk of acute myeloid leukemia.
How similar studies have gone: While research on pediatric cancers is ongoing, this specific investigation into the determinants of susceptibility in pediatric AML is relatively novel.
Where this research is happening
-
Van Andel Research Institute
Grand Rapids, United States Active
Researchers
- Principal investigator: Harmon, Lauren Marie — Van Andel Research Institute
- Study coordinator: Harmon, Lauren Marie
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.